European Equities Traded in US as ADRs Fall in Wednesday Trading

MT Newswires Live03-18 23:04

European equities traded in the US as American depositary receipts fell late Wednesday morning with the S&P Europe Select ADR Index dropping 0.9% to 1,734.7.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and petroleum refiner Equinor (EQNR), which rose 4% and 1.5%, respectively. They were followed by lenders Banco Bilbao Vizcaya Argentaria (BBVA) and ING (ING), which were up 0.3% and 0.2%, respectively.

The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and biotech firm BioNTech (BNTX), which fell 10% and 3.4%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and consumer goods company Unilever (UL), which were down 3.2% and 3%, respectively.

The gainers from the UK were led by biotech firm Trinity Biotech (TRIB) and oil and gas company BP (BP), which advanced 3.6% and 1.7%, respectively. They were followed by lender Barclays (BCS) and pharmaceutical company Silence Therapeutics (SLN), which increased 0.9% and 0.3%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Bicycle Therapeutics (BCYC), which shed 20% and 8.7%, respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Autolus Therapeutics (AUTL), which dropped 3.8% and 3.2%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment